Management of Renal Disease

  • Author: Mohamed G. Atta, MD, MPH (More Info)
  • Editors in Chief: Daniel R. Kuritzkes, MD; Joseph J. Eron, Jr., MD
  • Last Reviewed: 3/14/17 (What's New)

Summary

  • Cobicistat[FDA Cobicistat] and dolutegravir[FDA Dolutegravir] are each associated with serum creatinine increase that does not reflect changes in kidney function
  • Before starting either agent or their combinations, measure creatinine levels at baseline, after approximately 1 month on therapy, with the on-treatment level regarded as patient’s new “baseline” value

Action required

Keywords: Renal Complications, Treatment Complications

©2018 Clinical Care Options, LLC. All Rights Reserved.

The materials published via inPractice® reflect the views of the reviewers or authors of the material, not those of Clinical Care Options, LLC, the accredited provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.